Latest News
EU IMP QP Certification & Release Now Available at Simbec-Orion
01/05/2024
Simbec-Orion is delighted to share that as part of our ongoing strategy to provide full support and services to our clients, we have established an entity in the Netherlands through which we are able to import IMP into the EU, QP certify, and then release for use within clinical trial sites across the EU/EEA. This […]
Simbec-Orion and biotx.ai launch strategic partnership to de-risk early-stage drug development with AI supported clinical trial design.
26/10/2023
PRESS RELEASE: 26 October 2023 Simbec-Orion, a full-service mid-size CRO, and biotx.ai, a developer of AI-enabled causal modelling for drug development, have announced their strategic partnership to bring AI-powered insights and predictive models to support data-driven clinical trial design. Simbec-Orion, a specialist in oncology, rare disease, and clinical pharmacology studies, has over 45 years’ experience […]
Oxford Cannabinoid Technology partners with Simbec-Onion on milestone FIH Phase I study
10/10/2023
Simbec-Orion is honoured to have been trusted by Oxford Cannabinoid Technologies to run this milestone first-in-human Phase1 clinical trial of its lead compound, OCT461201 for Postherpetic Neuralgia (PHN) & Irritable Bowel Syndrome. Chief Scientific Officer, Valentino Parravicini recently discussed the significance of partnering with Simbec-Orion for the first-in-human Phase 1 clinical trial of the lead compound, […]
Simbec-Orion Expands Immunoassay Capability
19/07/2023
In line with our continuing investment in technology, we have recently expanded our immunoassay capability with the addition of a second Ella™ ELISA analyser from ProteinSimple. Utilising Simple PlexTM technology, EllaTM is providing Simbec-Orion clients with access to an extensive library of key immunoassays to support the measurement of both the immunogenic potential and pharmacodynamic […]
Simbec-Orion to conduct a Phase II clinical trial in pulmonary sarcoidosis patients for Molecure’s OATD-01
18/07/2023
Warsaw, 3rd July 2023 Molecure has signed an agreement to conduct a Phase II clinical trial for its lead molecule OATD-01, taking another important step in the development of this program. Read the full press release here
Welcome to Simon Jennings
05/07/2023
We are delighted to share that Simon Jennings as joined Simbec-Orion as Vice President, Data Sciences. Simon has over 35 years in the pharmaceutical and CRO industry comprising a variety of global leadership roles in Biostatistics, Data Management, Statistical Programming and Biometrics Project Management covering all phases of clinical research in Glaxo, Celltech, Eisai, Sandoz/Novartis […]
Le groupe Simbec-Orion a reçu l’accréditation pour la taxe Recherche & Développement
27/06/2023
Le groupe Simbec-Orion a reçu l’accréditation pour la taxe Recherche & Développement ‹‹CIR – Crédit d’Impôt Recherche›› qui donne droit aux entreprises françaises qui sont assujetties à l’impôt sur les sociétés en France, la capacité de réclamer un allégement fiscal sur les coûts générés pour des activités concernant la Recherche & Développement externalisée par le […]
